These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
214 related items for PubMed ID: 30267385
1. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D, RENEW MF-VEP Investigators. CNS Drugs; 2018 Dec; 32(12):1159-1171. PubMed ID: 30267385 [Abstract] [Full Text] [Related]
2. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S, RENEW Study Investigators. Lancet Neurol; 2017 Mar; 16(3):189-199. PubMed ID: 28229892 [Abstract] [Full Text] [Related]
6. Predictors of response to opicinumab in acute optic neuritis. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L, RENEW Study Investigators. Ann Clin Transl Neurol; 2018 Oct; 5(10):1154-1162. PubMed ID: 30349850 [Abstract] [Full Text] [Related]
7. Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. Pihl-Jensen G, Wanscher B, Frederiksen JL. Mult Scler; 2021 Mar; 27(3):391-400. PubMed ID: 32507033 [Abstract] [Full Text] [Related]